Form 4: Director Kroll Buys Haemonetics Stock

Haemonetics Director Mark W. Kroll purchased 1,400 shares of common stock at $70.56 per share.

Summary

• Director Mark W. Kroll acquired 1,400 shares of Haemonetics Corp (HAE) common stock.
• The transaction occurred on November 10, 2025, at a price of $70.56 per share.
• Following this purchase, Kroll beneficially owns 24,757 shares, which includes previously reported unvested restricted stock units.

Sentiment

Score: 8

Explanation: The purchase of company stock by a director is a strong positive signal, indicating confidence in the company's future performance and valuation.

Positives

• A director's purchase of company stock (insider buying) can signal confidence in the company's future prospects.
• Mark W. Kroll, a Director, increased his direct ownership in Haemonetics Corp by 1,400 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of future stock performance.

Key Dates

Recommendation

The director's purchase of company stock is a positive signal, indicating insider confidence. However, a single insider transaction typically warrants a 'hold' recommendation, encouraging investors to maintain their position or conduct further due diligence rather than an immediate 'buy' or 'sell' based solely on this filing.

Keywords

Haemonetics Corp, HAE, Insider Trading, Stock Purchase, Director, Form 4, Equity Acquisition